Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report.
FK 506 was used as a primary immunosuppressive agent in 125 cases of renal transplantation in a randomized trial comparing FK 506/prednisone with FK 506/azathioprine/prednisone. With a mean follow-up of 5.5 +/- 2.5 months, there has been a 6-month actuarial patient survival of 99% and graft survival of 88%. There is no difference thus far between the two-drug and three-drug groups, although there may be less rejection and diabetes in the three-drug group. These results suggest that FK 506 is a useful immunosuppressive agent in kidney transplantation.
Shapiro
R
R
Department of Surgery, University of Pittsburgh Health Science Center, Pennsylvania.
Jordan
M L
ML
Scantlebury
V P
VP
Fung
J J
JJ
Jensen
C
C
Vivas
C
C
McCauley
J
J
Irish
W D
WD
Mitchell
S
S
Demetris
A J
AJ
D000206:Actuarial Analysis; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D011241:Prednisone / Q000627:therapeutic use*; D016019:Survival Analysis; D016559:Tacrolimus / Q000627:therapeutic use*
D001379:Azathioprine; D011241:Prednisone; D016559:Tacrolimus